Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA

NCT00106418 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00106418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00106418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
May 7, 2003
Completion date
September 1, 2006
Enrollment
35 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastases, prostate cancer